PAOLI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.956
EU - Europa 1.214
AS - Asia 749
SA - Sud America 69
AF - Africa 15
OC - Oceania 7
Totale 4.010
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.938
RU - Federazione Russa 494
IT - Italia 292
SG - Singapore 224
CN - Cina 193
HK - Hong Kong 150
IE - Irlanda 91
SE - Svezia 78
KR - Corea 69
BR - Brasile 52
FI - Finlandia 49
DE - Germania 43
PL - Polonia 40
FR - Francia 35
JO - Giordania 32
VN - Vietnam 27
CH - Svizzera 26
GB - Regno Unito 23
IN - India 19
NL - Olanda 17
ID - Indonesia 13
ES - Italia 11
CA - Canada 8
AU - Australia 7
AR - Argentina 6
MX - Messico 6
CI - Costa d'Avorio 5
JP - Giappone 3
PK - Pakistan 3
RO - Romania 3
TR - Turchia 3
UA - Ucraina 3
VE - Venezuela 3
BJ - Benin 2
CL - Cile 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
IR - Iran 2
MM - Myanmar 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UY - Uruguay 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
IL - Israele 1
IQ - Iraq 1
JM - Giamaica 1
KE - Kenya 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MY - Malesia 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
PY - Paraguay 1
SA - Arabia Saudita 1
SN - Senegal 1
UZ - Uzbekistan 1
Totale 4.010
Salva come PNG Salva come JPEG
Città #
Santa Clara 493
Ashburn 231
Fairfield 191
Singapore 158
Hong Kong 128
Woodbridge 94
Chandler 93
Dublin 91
Seattle 81
Houston 74
Cambridge 72
Seoul 69
Florence 61
Wilmington 61
Hefei 44
Warsaw 40
Beijing 38
San Jose 38
Altamura 37
Lawrence 30
Princeton 28
Bern 26
Los Angeles 25
Ann Arbor 23
Dallas 22
Paris 22
Helsinki 21
Buffalo 20
Rome 20
Moscow 16
Munich 16
Shanghai 16
Clifton 15
Turku 15
London 14
Milan 14
Boston 13
Jakarta 12
Medford 12
Mumbai 11
Boardman 10
Bremen 10
New York 10
Ho Chi Minh City 8
Kent 8
Redondo Beach 8
The Dalles 8
Melbourne 7
Dearborn 6
Frosinone 6
San Diego 6
São Paulo 6
Abidjan 5
Atlanta 5
Lappeenranta 5
Latina 5
Toronto 5
Amsterdam 4
Barcelona 4
Cagliari 4
Dong Ket 4
Düsseldorf 4
Falls Church 4
Hanoi 4
Napoli 4
Norwalk 4
Siena 4
Andover 3
Chengdu 3
Faenza 3
Haiphong 3
Mexico City 3
Monza 3
Pomigliano d'Arco 3
Secaucus 3
Acquaviva delle Fonti 2
Amman 2
Ancona 2
Belo Horizonte 2
Bengaluru 2
Bergamo 2
Biên Hòa 2
Brescia 2
Brooklyn 2
Burghausen 2
Caponago 2
Casalecchio di Reno 2
Chennai 2
Cotonou 2
Elk Grove Village 2
Falkenstein 2
Fano 2
Foligno 2
Frankfurt am Main 2
Fuzhou 2
Gambettola 2
Genova 2
Hangzhou 2
Indianapolis 2
Johannesburg 2
Totale 2.717
Salva come PNG Salva come JPEG
Nome #
Sviluppo e gestione di studi clinici indipendenti di Fase I/II nelle Neoplasie Mieloproliferative Croniche 226
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 217
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group 214
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 212
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 189
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation 182
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 181
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 178
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 177
Kaposi Sarcoma in a patient treated with Ruxolitinib 171
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 169
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 165
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 156
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 153
Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms 153
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 151
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group 146
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 143
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs 140
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 134
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 127
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 125
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 124
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score 119
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 119
Totale 4.071
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.120
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.120
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021127 0 0 0 0 0 0 7 20 27 37 28 8
2021/2022154 5 11 15 4 3 7 5 20 11 6 22 45
2022/2023505 43 96 34 29 29 77 61 28 60 6 15 27
2023/2024233 12 20 24 21 17 24 5 68 6 13 12 11
2024/20251.472 49 115 79 237 374 244 38 108 44 57 66 61
2025/2026871 172 187 122 93 177 57 63 0 0 0 0 0
Totale 4.071